Fagron N.V.

Fagron N.V.

ARSUF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.78B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Fagron N.V.Fagron N.V.19.41.65%30%11.1
$36.25

Current Fair Value

37.3% upside

Undervalued by 37.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.78 Billion
Enterprise Value$2.28 Billion
Annual dividend$0.46
Dividend yield1.65%
Earnings per Share$1.24
Beta0.39
Outstanding Shares73,295,000

Return

Return on Equity29.84%ROE
Return on Assets11.63%
Return on Invested Capital23.27%

Valuation & Multiples

P/E Ratio19.36P/E Ratio
PEG1230.16PEG
Price to Sales1.02Price to Sales
Price to Book Ratio3.3Price to Book Ratio
Enterprise Value to Revenue1.17
Enterprise Value to EBIT7.87
Enterprise Value to Net Income12
Total Debt to Enterprise0.28
Debt to Equity1.07Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
July 30, 2026
EPS
$0.72
Reported
Revenue
$630.99 M
Est. $619.57 M

Next Earnings Call

Expected Date
February 11, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Fagron N.V.

4,134 employees
CEO: Rafael Padilla

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond ...